Ask AI
ProCE Banner Activity

Decera: 再発・難治性慢性リンパ性白血病または小リンパ性リンパ腫に対する新しい治療法の最新臨床進歩に関する患者向けガイド

PDF

この患者向けのリソースは、慢性リンパ性白血病または小リンパ性リンパ腫に関する各研究の主要な発見やポイントをまとめたものです。これらのリソースは、各研究を患者向けのコミュニケーション文書としてまとめ、患者とその医療提供者が重要な共同意思決定の会話に備えることができるようにしています。

Released: April 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with relapsed/refractory CLL globally.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with relapsed/refractory CLL

  • Appraise the potential clinical implications of new data on novel targeted and cellular therapies for treatment selection and sequencing in patients with relapsed/refractory CLL

  • Support effective shared decision-making through patient education and resources on the potential clinical implications of recently presented data for relapsed/refractory CLL

Disclosure

Primary Author

Dai Maruyama, (丸山 大), MD, PhD, has no relevant financial relationships to disclose.